News Focus
News Focus
icon url

kris_kade

03/04/18 7:08 PM

#217671 RE: DewDiligence #217668

Good that Sakura-3 is open label; so investors can track any safety issue.

The long trials that Revance has gone thru speaks loud as how high the bar is when it comes to ‘Botox’ approval.

I just hope they keep their laser focus on getting BLA filed as quickly as possible. Execution, execution and execution. Biosimilars can wait.